Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Frankie1x, we have several major shareholders, each holding less than 5% of the company's shares. This percentage serves as the requisite threshold for UK companies to inform the market of any changes in their holdings through a TR1 notification.
Jupiter Asset Management Ltd 4.364 %
Premier Fund Managers Ltd. 3.836 %
LGT Capital Partners AG (Investment Management) 3.669 %
KW Investment Management Ltd. 2.641 %
Jarvis Investment Management Ltd. 1.680 %
Given the substantial number of shares traded at the end of last month, I am inclined to believe that at least two major shareholders have offloaded their shares to the market and cashed out.
Regardless, the past is behind us, and we've observed a nice buying momentum gaining traction since the start of this week. I can see the share price smoothly rise back to the 4s from its current level. The technical chart is currently indicating a significant oversold condition on both the weekly and daily charts, making it an appealing prospect for chart and momentum traders as well.
Tax-loss harvesting strategy:
Selling shares at a loss before the end of the tax year allows holders to offset capital gains and reduce their overall taxable income. This strategy, known as tax-loss harvesting, helps minimize taxes by utilizing investment losses to counterbalance gains elsewhere in their portfolio.
Here you go :
https://www.youtube.com/watch?v=ZPjiX-VY3Cg
22 Feb 2024
Gateshead-based commercial stage pharmaceutical firm Shield Therapeutics has revised its breakeven plans, but hailed a period of progress.
In a trading update for the year ended 31 December 2023, Shield Therapeutics said that it expects to turn cash flow positive in the second half of 2025, instead of its initial target of year-end 2024.
The update follows the company identifying that its projection methodology used by its third-party data provider had resulted in an overstatement of total prescriptions in 2023.
"This development was partly responsible for the group not achieving previously indicated guidance of total prescriptions in FY23 of 100k to 130k", Shield said.
"With these revised prescription numbers, Shield is revisiting its previously communicated guidance and plans to provide additional updates at the time of the company's final results, expected to be published in April 2024", it added.
In spite of this, total 2023 revenue and income stood at $17.5m, which was a 2.8x increase over FY22.
Cash at the end of December was $13.9m.
Chief executive Greg Madison said: "The progress made in the market in 2023 has shown us that the opportunity for Accrufer continues to be significant.
"Quarterly prescription numbers grew throughout the year and we saw a significant improvement in the average net selling price in the second half.
"I'm also excited our new CFO, Santosh Shanbhag, has joined the team bringing both strategic and financial leadership to our organisation. Our partnership with Viatris continues to progress very well and we remain steadfast in our goal to make Accrufer the oral iron of choice for patients."
Link: https://shorturl.at/twCD5
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s third-quarter trading update for Accrufer in the US market shows its tie-up with Viatris and expanded sales team are “bearing fruit”, according to analysts.
Accrufer is a non-salt based oral therapy used to treat iron deficiency in adults.
Analysts at Cavendish said key performance indicators such as total scrips, new scrips, retention rate, and net realised price are all showing significant improvement compared to the first half of 2023.
The number of US representatives promoting Accrufer increased from 16 to 30 in the first quarter of 2023, and by May 2023, a total of 100 had been trained to sell the product.
Third quarter unaudited sales were US$4.1 million, above the broker’s forecasts of US$3.6 million, and the company said trading is in-line with expectations.
Link: https://www.proactiveinvestors.co.uk/companies/news/1036099/shield-therapeutics-is-bearing-fruit-says-cavendish-1036099.html
I agree Drizzy90, the market witnessed the highest daily volume in the company's history, likely triggered by a significant sell-off from a major shareholder. AOP Health & Nestle have been steadfast supporters of Shield Therapeutics, but other prominent funds maintain positions below 4%.
I suspect Jupiter Asset Management to be the seller, and it seems they have either completed or are nearing the end of their selling activity. The selling pressure has eased, evident from the decreased intensity, and Level 2 data indicates a robust buying interest with strong support in the BID.
The technical chart is heavily oversold, suggesting a probable rebound to above 3p before the end of the day. Additionally, the upcoming webinar tomorrow could potentially soothe the market, paving the way for a recovery back to the 4s by the weekend.
Don’t you get board of being the resident deramper on here , people are aware that you are one of the quid -per-post minions but honestly, isn’t there a more fulfilling way to earn a living? Life is too short to spend it in this manner.